1h Free Analyst Time
According to the recently published report, Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 70 molecules. Out of which approximately 59 molecules are developed by companies and remaining by the universities/institutes.Speak directly to the analyst to clarify any post sales queries you may have.
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson's. In Parkinson's it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
The report outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 8, 28 and 16 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 9 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Lewy Body Dementia, Alzheimer's Disease, Neurodegenerative Diseases, Familial Amyloid Neuropathies, Amyloidosis, Autism, Chronic Traumatic Encephalopathy (CTE), Constipation, Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), Dementia, Dementia Associated With Alzheimer's Disease, Frontotemporal Dementia (FTD), Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Progressive Supranuclear Palsy, Psychosis, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
- Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development
- ABL Bio Inc
- AC Immune SA
- Alterity Therapeutics Ltd
- Annovis Bio Inc
- Aprinoia Therapeutics Inc
- Arvinas Inc
- AstraZeneca Plc
- AUM LifeTech Inc
- BioArctic AB
- Chimerna Therapeutics Inc
- DegenRx BV
- Denali Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Enterin Inc
- Fulcrum Therapeutics Inc
- Genmab AS
- ICB International Inc
- Ionis Pharmaceuticals Inc
- ND Biosciences SA
- Neuramedy Co Ltd
- Neurimmune Holding AG
- Neuropore Therapies Inc
- nLife Therapeutics SL
- Nuravax Inc
- Prazer Therapeutics
- Priavoid GmbH
- Primary Peptides Inc
- Proclara Biosciences Inc
- ProMIS Neurosciences Inc
- Prothena Corp Plc
- ResQ Biotech
- Seelos Therapeutics, Inc.
- Selonterra Inc
- Shape Therapeutics Inc
- Synapss Therapeutics Inc
- Teva Pharmaceutical Industries Ltd
- Treventis Corp
- UCB SA
- UniQure NV
- Vaxxinity Inc
- Wren Therapeutics Ltd
- Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles
- AAV hmAb 1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ABBV-0805 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ABL-301 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ACI-5755 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ACI-7104 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AHT-434 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Alpha Syn Degrader - Drug Profile
- Product Description
- Mechanism Of Action
- Alpha Synuclein - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Alpha-Synuclein - Drug Profile
- Product Description
- Mechanism Of Action
- AMT-210 - Drug Profile
- Product Description
- Mechanism Of Action
- Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile
- Product Description
- Mechanism Of Action
- Antisense RNAi Oligonucleotide to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Antisense RNAi Oligonucleotides to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ANVS-405 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Aptamer to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- ASOA-19 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ATV:aSyn - Drug Profile
- Product Description
- Mechanism Of Action
- AV-1950D - Drug Profile
- Product Description
- Mechanism Of Action
- AV-1950R - Drug Profile
- Product Description
- Mechanism Of Action
- buntanetap tartrate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- C-terminal Alpha Synuclein - Drug Profile
- Product Description
- Mechanism Of Action
- CLR-01 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Drug to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ENT-01 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Fusion Proteins to Inhibit ABPP, MAPT and NACP for Amyloidosis and Neurodegenerative Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- ION-464 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LuAF-82422 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MEDI-1341 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibodies to Inhibit Alpha Synuclein for Multiple System Atrophy - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- Morphomer a-Syn - Drug Profile
- Product Description
- Mechanism Of Action
- ND-001 - Drug Profile
- Product Description
- Mechanism Of Action
- NLFPD-1233 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NM-401 - Drug Profile
- Product Description
- Mechanism Of Action
- NM-402 - Drug Profile
- Product Description
- Mechanism Of Action
- NM-403 - Drug Profile
- Product Description
- Mechanism Of Action
- NPT-088 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NPT-10018A - Drug Profile
- Product Description
- Mechanism Of Action
- NPT-189 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Parkinson's Disease (SNCA A53T, LRRK2 G2019S) - Drug Profile
- Product Description
- Mechanism Of Action
- PD-04 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PD-1601 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PD-1602 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PMN-442 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PP-003 - Drug Profile
- Product Description
- Mechanism Of Action
- PR-004 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- prasinezumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PRI-100 - Drug Profile
- Product Description
- Mechanism Of Action
- PRX-303 - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Peptides to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- SHP-201 - Drug Profile
- Product Description
- Mechanism Of Action
- SLS-004 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SLS-007 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit SNCA for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit Alpha Synuclein for Neurodegenerative Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- SMQ-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SNP-201 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TEV-56286 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TEV-56287 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- UB-312 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- UCB-0599 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- UCB-7853 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products
- Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Discontinued Products
- Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones
- Featured News & Press Releases
- Nov 07, 2022: Alterity Therapeutics announces presentation of data from the bioMUSE natural history study at the American Autonomic Society Annual Meeting
- Oct 26, 2022: Alterity Therapeutics announces presentation of MRI data from the bioMUSE natural history study at the American Neurological Association Annual Meeting
- Oct 14, 2022: Alterity Therapeutics obtains approval in Australia to begin MSA therapy
- Oct 11, 2022: Annovis Bio announces publication of phase 2a clinical data in The Journal of Prevention of Alzheimer's Disease
- Oct 06, 2022: Annovis Bio announces FDA authorization to proceed with phase 2/3 trial for buntanetap in Alzheimer's Disease
- Sep 26, 2022: Alterity Therapeutics announces presentation of wearable sensor data from the bioMUSE natural history study at the International Congress of Parkinson's Disease and Movement Disorders
- Sep 20, 2022: Alterity Therapeutics receives U.S. FDA approval for Investigational New Drug application for ATH434 for the treatment of Multiple System Atrophy
- Sep 13, 2022: Annovis Bio announces publication of patents covering the treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
- Aug 25, 2022: Alterity begins Phase II multiple system atrophy therapy trial in UK
- Aug 24, 2022: Annovis Bio doses first subject in Phase III Parkinson’s trial
- Aug 24, 2022: Seelos Therapeutics receives a research and development grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004
- Jul 08, 2022: Annovis Bio receives FDA notice to advance Phase III Parkinson’s trial
- Jul 06, 2022: Alterity Therapeutics doses first patient in ATH434 phase 2 clinical trial in multiple system atrophy
- Jun 30, 2022: Alterity receives a $4.1 million R&D Tax Incentive Refund
- Jun 24, 2022: Alterity obtains authorisation in Italy for Phase II trial of multiple system atrophy therapy
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by ABL Bio Inc, 2022
- Pipeline by AC Immune SA, 2022
- Pipeline by Alterity Therapeutics Ltd, 2022
- Pipeline by Annovis Bio Inc, 2022
- Pipeline by Aprinoia Therapeutics Inc, 2022
- Pipeline by Arvinas Inc, 2022
- Pipeline by AstraZeneca Plc, 2022
- Pipeline by AUM LifeTech Inc, 2022
- Pipeline by BioArctic AB, 2022
- Pipeline by Chimerna Therapeutics Inc, 2022
- Pipeline by DegenRx BV, 2022
- Pipeline by Denali Therapeutics Inc, 2022
- Pipeline by Eisai Co Ltd, 2022
- Pipeline by Eli Lilly and Co, 2022
- Pipeline by Enterin Inc, 2022
- Pipeline by Fulcrum Therapeutics Inc, 2022
- Pipeline by Genmab AS, 2022
- Pipeline by ICB International Inc, 2022
- Pipeline by Ionis Pharmaceuticals Inc, 2022
- Pipeline by ND Biosciences SA, 2022
- Pipeline by Neuramedy Co Ltd, 2022
- Pipeline by Neurimmune Holding AG, 2022
- Pipeline by Neuropore Therapies Inc, 2022
- Pipeline by nLife Therapeutics SL, 2022
- Pipeline by Nuravax Inc, 2022
- Pipeline by Prazer Therapeutics, 2022
- Pipeline by Priavoid GmbH, 2022
- Pipeline by Primary Peptides Inc, 2022
- Pipeline by Proclara Biosciences Inc, 2022
- Pipeline by ProMIS Neurosciences Inc, 2022
- Pipeline by Prothena Corp Plc, 2022
- Pipeline by ResQ Biotech, 2022
- Pipeline by Seelos Therapeutics, Inc., 2022
- Pipeline by Selonterra Inc, 2022
- Pipeline by Shape Therapeutics Inc, 2022
- Pipeline by Synapss Therapeutics Inc, 2022
- Pipeline by Teva Pharmaceutical Industries Ltd, 2022
- Pipeline by Treventis Corp, 2022
- Pipeline by UCB SA, 2022
- Pipeline by UniQure NV, 2022
- Pipeline by Vaxxinity Inc, 2022
- Pipeline by Wren Therapeutics Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ABL Bio Inc
- AC Immune SA
- Alterity Therapeutics Ltd
- Annovis Bio Inc
- Aprinoia Therapeutics Inc
- Arvinas Inc
- AstraZeneca Plc
- AUM LifeTech Inc
- BioArctic AB
- Chimerna Therapeutics Inc
- DegenRx BV
- Denali Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Enterin Inc
- Fulcrum Therapeutics Inc
- Genmab AS
- ICB International Inc
- Ionis Pharmaceuticals Inc
- ND Biosciences SA
- Neuramedy Co Ltd
- Neurimmune Holding AG
- Neuropore Therapies Inc
- nLife Therapeutics SL
- Nuravax Inc
- Prazer Therapeutics
- Priavoid GmbH
- Primary Peptides Inc
- Proclara Biosciences Inc
- ProMIS Neurosciences Inc
- Prothena Corp Plc
- ResQ Biotech
- Seelos Therapeutics, Inc.
- Selonterra Inc
- Shape Therapeutics Inc
- Synapss Therapeutics Inc
- Teva Pharmaceutical Industries Ltd
- Treventis Corp
- UCB SA
- UniQure NV
- Vaxxinity Inc
- Wren Therapeutics Ltd
